Modulation of CD19 surface expression in B cell acute lymphoblastic leukemia

Immunotherapeutic targeting of the surface glycoprotein CD19 has markedly improved outcomes in patients with relapsed and refractory B cell progenitor acute lymphoblastic leukemia. Genome-wide CRISPR–Cas9 screening identifies modulators of CD19 mRNA processing that affect the abundance of the surfac...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Research Briefing
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510525/
https://www.ncbi.nlm.nih.gov/pubmed/36151397
http://dx.doi.org/10.1038/s41590-022-01316-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510525/
https://www.ncbi.nlm.nih.gov/pubmed/36151397
http://dx.doi.org/10.1038/s41590-022-01316-w

Ejemplares similares